医学
格雷夫斯病
内科学
甲状腺
Graves眼病
特拉布
内分泌学
眼球突出
甲状腺炎
出处
期刊:Chinese Journal of Endocrinology and Metabolism
日期:2016-10-25
卷期号:32 (10): 886-888
标识
DOI:10.3760/cma.j.issn.1000-6699.2016.10.018
摘要
In March 2016, European Thyroid Association/European Group on Graves′ Orbitopathy(EUGOGO)published a guideline for the management of Graves′ orbitopathy(GO). Compared with the consensus statement of EUGOGO on management of GO, the guideline presents the selenium supplementation for mild GO, the first-line and second-line therapy for moderate-to-severe and active GO and the surgery for moderate-to-severe and inactive GO in detail, which adopts grading of recommendations and level of evidence and incorporates the results of recent clinical randomized trials. The guideline includes 17 specific recommendations. The treatment of patients with severe GO, and those who do not response to glucocoticoids is still a challenge. The novel agents will have to be awaited with the results of clinical studies. (Chin J Endocrinol Metab, 2016, 32: 886-888)
Key words:
Graves′ orbitopathy; Selenium; Glucocorticoids; Rituximab
科研通智能强力驱动
Strongly Powered by AbleSci AI